-
Electronic (PDF)
-
Site License
-
Enterprisewide
Type 2 Diabetes - Global Drug Forecasts and Treatment Analysis to 2020
GlobalData, February 2012, Pages: 517
Type 2 Diabetes - Global Drug Forecasts and Treatment Analysis to 2020
Summary
GlobalData, the industry analysis specialist, has released its new report, “Type 2 Diabetes - Global Drug Forecasts and Treatment Analysis to 2020”. The report is an essential source of information and analysis on the global type 2 diabetes therapeutics market. The report provides comprehensive information on type 2 diabetes, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the global type 2 diabetes therapeutics market. It analyses the treatment usage patterns in the global type 2 diabetes therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global type 2 diabetes sector. It quantifies the unmet need in the global type 2 diabetes therapeutics market as well as in the individual markets such as the US and the top five countries in Europe, highlighting the opportunity for future players.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData analysis shows that the global type 2 diabetes therapeutics market was worth $23.7 billion in 2011. Between 2002 and 2011, the market grew at a rate of 11.8%. By 2020, the market is expected to be worth $45.1 billion, indicating a Compound Annual Growth Rate (CAGR) of 7.4% between 2011 and 2020.
The global type 2 diabetes therapeutics market is very attractive and has primarily been driven by the growth in patient volume and the annual cost of therapy. Patient volume has been driven by the increased incidence and prevalence of diabetes and the growth in treatment usage patterns, such as the diseased population, the treatment-seeking population, the diagnosed population and the prescription population. The annual cost of type 2 diabetes therapy was driven by the uptake of newly approved drugs, such as Actos (pioglitazone) and Avandia (rosiglitazone) until 2006 and the launch of new therapies, such as Levemir (insulin detemir), Byetta (exenatide), Januvia (sitagliptin), and Victoza (liraglutide). The annual cost of therapy was also driven by the increased use of multiple drugs per patient and the adoption of combination therapies, such as Actoplusmet (pioglitazone and metformin), Avandamet (rosiglitazone and metformin), Janumet (sitagliptin and metformin) and Duetact (pioglitazone and glimepiride) in the first-line and second-line treatment of type 2 diabetes patients.
Metformin, alone or in combination with other oral agents, has become the standard of care for the first-line treatment of type 2 diabetes patients. Similarly, metformin in combination with DPP4 inhibitors or GLP-1 analogs has become one of the most commonly prescribed treatment options for type 2 diabetes. In 2011, within the countries analyzed in this report (the US, EU5, Japan and BRIC countries), the US was the leading market with an estimated market share of 52.7%. Japan was the second leading market with an approximate market share of 12.8%, closely followed by Germany with an approximate market share of 7.5%. In 2011, Lantus was the leading drug, with approximate sales worth $3.6 billion and a market share of 18%. Januvia/Janumet, the DPP4 inhibitor was the second leading drug, with approximate sales of $3.4 billion and a market share of 17.1%. Actos was the third leading drug, with an approximate sales value of $1.9 billion and a market share of 9.6%.
Scope
The scope of the report includes -
- An overview of type 2 diabetes which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized global type 2 diabetes therapeutics market revenue, annual cost of therapy and treatment usage patterns data by stage of the disease from 2002 to 2011, forecast for 9 years to 2020.
- Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France Japan and BRIC countries that include Brazil, Russia, India and China
- Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.
- Competitor assessment including drug launch analysis and drug sales forecasts.
- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM activities, product positioning and drug sales forecast.
- Analysis of unmet need in the market and target product profile including opportunity for target product.
- Technology trends analytic framework to assess strength of pipeline.
- Pipeline analysis data providing a split by stage of the disease and line of therapy across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include SGLT-2 inhibitors, 11ß HSD inhibitors, CCR2 antagonists, selective inhibitors of fructose 1, 6-bisphosphatase, immunomodulators, cortisol synthesis inhibitors, interleukin-1ß antagonists, gastrin-releasing peptide (GRP) receptor agonists, GPR 119 agonists, TLR-4 receptor agonists, FXR antagonists and GSK-3 inhibitors.
- Clinical trials mapping for type 2 diabetes in different regions.
- An overview of the most promising drugs’ including clinical study details, efficacy, safety, collaboration agreements, marketing rights, and launch analysis and drug sales forcasts to 2020.
- Analysis of the current and future market competition in the global type 2 diabetes therapeutics market.
- Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Astellas Pharma Inc, Takeda Pharmaceuticals, Boehringer Ingelheim, Novartis, Sanofi, J&J and Hoffmann La Roche.
- Analysis of licensing agreements during 2008-2011 in the type 2 diabetes therapeutics market. M&A analysis which includes M&A deals by size and geography.
- Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
- Direct quotes from key opinion leaders (KOL) or physicians in the type 2 diabetes therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop business strategies and perform superior market quantification analysis by
- Understanding the trends shaping and driving the global type 2 diabetes therapeutics market.
- Understanding treatment preferences of physicians in disease state and across treatment flow.
- Accessing market sizing, forecasts and quantified growth opportunities in the global type 2 diabetes therapeutics market till 2020.
- Quantifying patient population in the global type 2 diabetes market to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
- Performing benchmarking analysis and growth opportunities against currently marketed products
- Identifying market entry points based on safety, efficacy, and pricing parameters.
- Assessing competitiveness of products in market by understanding the strength and weakness of current competition.
- Develop and design your in-licensing and out-licensing strategies by
- Taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.
- Assessing strength of pipeline bases on first in class, me-too, generic and lifecycle management of products.
- Track drug sales in the global type 2 diabetes therapeutics market from 2002 to 2020.
- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
- What’s the next big thing in the global type 2 diabetes therapeutics market landscape? Identify, understand and capitalize.
Keywords
Market forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products, pipeline, promising drugs, future players, key companies, strategic competitor assessment, market characterization, implications for future market, mechanism of action, oncology, cancer, treatment guideline, target product profile, clinician's endpoints, disease overview, colorectal cancer drug sales, US colorectal cancer market, UK colorectal cancer market, France colorectal cancer market, Germany colorectal cancer market, Italy colorectal cancer market, Spain colorectal cancer market, Japan colorectal cancer market, BRIC colorectal cancer market, Brazil, Russia, India, China
1
1
1.1 List of Tables
1.2 List of Figures
2 Disease Overview
2.1 Overview
2.2 Epidemiology
2.3 Economic Impact of Diabetes
2.4 Etiology
2.5 Symptoms
2.6 Diagnosis
2.7 Pathology
2.8 Treatment
2.9 Treatment Guidelines
2.10 GlobalData In-Depth Report Guidance
3 Market Characterization
3.1 Global
3.2 The US
3.3 The UK
3.4 Germany
3.5 France
3.6 Italy
3.7 Spain
3.8 Japan
3.9 Brazil
3.10 India
3.11 China
3.12 Russia
3.13 Key Takeaway
4 Type 2 Diabetes Therapeutics - Opportunity and Unmet Need
4.1 Unmet Need
4.2 Opportunity for Target Products
4.3 Target Product Profile
4.4 Key Takeaway
5 Type 2 Diabetes Therapeutics - Competitive Assessment
5.1 Strategic Competitive Assessment
5.2 Launch Analysis and Sales Forecasts
5.3 Product Profiles
5.4 Recently Launched or Approved Products in the Market
5.5 Partners in Development - Marketed Products
5.6 Key Takeaway
6 Type 2 Diabetes Therapeutics - Pipeline Assessment
6.1 Overview
6.2 Pipeline Analysis by Phase of Development
6.3 Pipeline by Mechanism of Action
6.4 Strategic Pipeline Assessment
6.5 Trends in Type 2 Diabetes Pipeline
6.6 Type 2 Diabetes Pipeline - Regulatory Filing
6.7 Type 2 Diabetes Pipeline - Phase III
6.8 Type 2 Diabetes Pipeline - Phase II
6.9 Type 2 Diabetes Pipeline - Phase I
6.10 Type 2 Diabetes Pipeline - Preclinical and Discovery
6.11 Most Promising Drug Profiles
6.12 Partners in Development - Pipeline Products
6.13 Key Takeaway
7 Type 2 Diabetes Therapeutics - Clinical Trials Mapping
7.1 Clinical Trials
7.2 Patient Recruitment
8 Type 2 Diabetes Therapeutics - Implications for Future Market Competition
8.1 Key Events Impacting the Future Market
8.2 Market Impact Analysis
8.3 Future Market Scenario
8.4 Company Analysis
9 Type 2 Diabetes Therapeutics - Future Market Players
9.1 Introduction
9.2 Novo Nordisk
9.3 Amylin Pharmaceuticals
9.4 Takeda Pharmaceuticals
9.5 Boehringer Ingelheim
9.6 Eli Lilly and Company
9.7 GlaxoSmithKline
9.8 Novartis
9.9 Sanofi
9.10 F. Hoffmann La Roche
9.11 Bristol-Myers Squibb
9.12 Johnson & Johnson (J&J)
9.13 Astellas Pharma Inc.
10 Deals Analysis
10.1 Key Highlights
10.2 Key Deals Analysis
10.3 Deals Analysis by Geography
10.4 Deals Analysis by Deal Size
11 Type 2 Diabetes Therapeutics - Expert Opinion
11.1 Expert Opinion
12 Type 2 Diabetes Therapeutics - Appendix
12.1 Definitions
12.2 Acronyms
12.3 Research Methodology
12.4 Contact Us
12.5 Disclaimer
12.6 Bibliography
1.1 List of Tables
Table 1: Type 2 Diabetes, Global, Prevalence Estimates for the 20-79 Age Group (million), 2000-2030
Table 2: Type 2 Diabetes, Top 10 Countries, Prevalence (million), 2010 and 2030
Table 3: Type 2 Diabetes, Top 10 Countries, Health Expenditures ($bn), 2011
Table 4: Type 2 Diabetes Therapeutics Market, Fasting Plasma Glucose Tests
Table 5: Type 2 Diabetes Therapeutics Market, Global, Sales Value ($bn), 2002-2011
Table 6: Type 2 Diabetes Therapeutics Market, Global, Sales Value ($bn) by Country, 2002-2011
Table 7: Type 2 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2011
Table 8: Type 2 Diabetes Therapeutics Market, Global, Patient Volume (million), 2002-2011
Table 9: Type 2 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2011
Table 10: Type 2 Diabetes Therapeutics Market, Global, Sales Value ($bn), 2011-2020
Table 11: Type 2 Diabetes Therapeutics Market, Global, Sales Value ($bn) by Country, 2011-2020
Table 12: Type 2 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2020
Table 13: Type 2 Diabetes Therapeutics Market, Global, Patient Volume (million), 2011-2020
Table 14: Type 2 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (million), 2011-2020
Table 15: Type 2 Diabetes Therapeutics Major Markets, Drug Sales ($m), 2002-2011
Table 16: Type 2 Diabetes Therapeutics Major Markets, Drug Sales ($m), 2012-2020
Table 17: Type 2 Diabetes Therapeutics Market, The US, Sales Value ($bn), 2002-2011
Table 18: Type 2 Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2002-2011
Table 19: Type 2 Diabetes Therapeutics Market, The US, Patient Volume (million), 2002-2011
Table 20: Type 2 Diabetes Therapeutics Market, The US, Treatment Usage Patterns (million), 2002-2011
Table 21: Type 2 Diabetes Therapeutics Market, The US, Sales Value ($bn), 2011-2020
Table 22: Type 2 Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2011-2020
Table 23: Type 2 Diabetes Therapeutics Market, The US, Patient Volume (million), 2011-2020
Table 24: Type 2 Diabetes Therapeutics Market, The US, Treatment Usage Patterns (million), 2011-2020
Table 25: Type 2 Diabetes Therapeutics Market, US, Drug Sales ($m), 2002-2011
Table 26: Type 2 Diabetes Therapeutics Market, US, Drug Sales ($m), 2012-2020
Table 27: Type 2 Diabetes Therapeutics Market, The UK, Sales Value ($m), 2002-2011
Table 28: Type 2 Diabetes Therapeutics Market, The UK, Annual Cost of Therapy ($), 2002-2011
Table 29: Type 2 Diabetes Therapeutics Market, The UK, Patient Volume (million), 2002-2011
Table 30: Type 2 Diabetes Therapeutics Market, The UK, Treatment Usage Patterns (million), 2002-2011
Table 31: Type 2 Diabetes Therapeutics Market, The UK, Sales Value ($m), 2011-2020
Table 32: Type 2 Diabetes Therapeutics Market, The UK, Annual Cost of Therapy ($), 2011-2020
Table 33: Type 2 Diabetes Therapeutics Market, The UK, Patient Volume (million), 2011-2020
Table 34: Type 2 Diabetes Therapeutics Market, The UK, Treatment Usage Patterns (million), 2011-2020
Table 35: Type 2 Diabetes Therapeutics Market, The UK, Drug Sales ($m), 2002-2011
Table 36: Type 2 Diabetes Therapeutics Market,The UK, Drug Sales ($m), 2012-2020
Table 37: Type 2 Diabetes Therapeutics Market, Germany, Sales Value ($m), 2002-2011
Table 38: Type 2 Diabetes Therapeutics Market, Germany, Annual Cost of Therapy ($), 2002-2011
Table 39: Type 2 Diabetes Therapeutics Market, Germany, Patient Volume (million), 2002-2011
Table 40: Type 2 Diabetes Therapeutics Market, Germany, Treatment Usage Patterns (million), 2002-2011
Table 41: Type 2 Diabetes Therapeutics Market, Germany, Sales Value ($m), 2011-2020
Table 42: Type 2 Diabetes Therapeutics Market, Germany, Annual Cost of Therapy ($), 2011-2020
Table 43: Type 2 Diabetes Therapeutics Market, Germany, Patient Volume (million), 2011-2020
Table 44: Type 2 Diabetes Therapeutics Market, Germany, Treatment Usage Patterns (million), 2011-2020
Table 45: Type 2 Diabetes Therapeutics Market, Germany, Drug Sales ($m), 2002-2011
Table 46: Type 2 Diabetes Therapeutics Market, Germany, Drug Sales ($m), 2012-2020
Table 47: Type 2 Diabetes Therapeutics Market, France, Sales Value ($m), 2002-2011
Table 48: Type 2 Diabetes Therapeutics Market, France, Annual Cost of Therapy ($), 2002-2011
Table 49: Type 2 Diabetes Therapeutics Market, France, Patient Volume (million), 2002-2011
Table 50: Type 2 Diabetes Therapeutics Market, France, Treatment Usage Patterns (million), 2002-2011
Table 51: Type 2 Diabetes Therapeutics Market, France, Sales Value ($m), 2011-2020
Table 52: Type 2 Diabetes Therapeutics Market, France, Annual Cost of Therapy ($), 2011-2020
Table 53: Type 2 Diabetes Therapeutics Market, France, Patient Volume (million), 2011-2020
Table 54: Type 2 Diabetes Therapeutics Market, France, Treatment Usage Patterns (million), 2011-2020
Table 55: Type 2 Diabetes Therapeutics Market, France, Drug Sales ($m), 2002-2011
Table 56: Type 2 Diabetes Therapeutics Market, France, Drug Sales ($m), 2012-2020
Table 57: Type 2 Diabetes Therapeutics Market, Italy, Sales Value ($m), 2002-2011
Table 58: Type 2 Diabetes Therapeutics Market, Italy, Annual Cost of Therapy ($), 2002-2011
Table 59: Type 2 Diabetes Therapeutics Market, Italy, Patient Volume (million), 2002-2011
Table 60: Type 2 Diabetes Therapeutics Market, Italy, Treatment Usage Patterns (million), 2002-2011
Table 61: Type 2 Diabetes Therapeutics Market, Italy, Sales Value ($m), 2011-2020
Table 62: Type 2 Diabetes Therapeutics Market, Italy, Annual Cost of Therapy ($), 2011-2020
Table 63: Type 2 Diabetes Therapeutics Market, Italy, Patient Volume (million), 2011-2020
Table 64: Type 2 Diabetes Therapeutics Market, Italy, Treatment Usage Patterns (million), 2011-2020
Table 65: Type 2 Diabetes Therapeutics Market, Italy, Drug Sales ($m), 2002-2011
Table 66: Type 2 Diabetes Therapeutics Market, Italy, Drug Sales ($m), 2012-2020
Table 67: Type 2 Diabetes Therapeutics Market, Spain, Sales Value ($m), 2002-2011
Table 68: Type 2 Diabetes Therapeutics Market, Spain, Annual Cost of Therapy ($), 2002-2011
Table 69: Type 2 Diabetes Therapeutics Market, Spain, Patient Volume (million), 2002-2011
Table 70: Type 2 Diabetes Therapeutics Market, Spain, Treatment Usage Patterns (million), 2002-2011
Table 71: Type 2 Diabetes Therapeutics Market, Spain, Sales Value ($m), 2011-2020
Table 72: Type 2 Diabetes Therapeutics Market, Spain, Annual Cost of Therapy ($), 2011-2020
Table 73: Type 2 Diabetes Therapeutics Market, Spain, Patient Volume (million), 2011-2020
Table 74: Type 2 Diabetes Therapeutics Market, Spain, Treatment Usage Patterns (million), 2011-2020
Table 75: Type 2 Diabetes Therapeutics Market, Spain, Drug Sales ($m), 2002-2011
Table 76: Type 2 Diabetes Therapeutics Market, Spain, Drug Sales ($m), 2012-2020
Table 77: Type 2 Diabetes Therapeutics Market, Japan, Sales Value ($m), 2002-2011
Table 78: Type 2 Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2011
Table 79: Type 2 Diabetes Therapeutics Market, Japan, Patient Volume (million), 2002-2011
Table 80: Type 2 Diabetes Therapeutics Market, Japan, Treatment Usage Patterns (million), 2002-2011
Table 81: Type 2 Diabetes Therapeutics Market, Japan, Sales Value ($m), 2011-2020
Table 82: Type 2 Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011-2020
Table 83: Type 2 Diabetes Therapeutics Market, Japan, Patient Volume (million), 2011-2020
Table 84: Type 2 Diabetes Therapeutics Market, Japan, Treatment Usage Patterns (million), 2011-2020
Table 85: Type 2 Diabetes Therapeutics Market, Japan, Drug Sales ($m), 2002-2011
Table 86: Type 2 Diabetes Therapeutics Market, Japan, Drug Sales ($m), 2012-2020
Table 87: Type 2 Diabetes Therapeutics Market, Brazil, Sales Value ($m), 2002-2011
Table 88: Type 2 Diabetes Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2002-2011
Table 89: Type 2 Diabetes Therapeutics Market, Brazil, Patient Volume (million), 2002-2011
Table 90: Type 2 Diabetes Therapeutics Market, Brazil, Treatment Usage Patterns (million), 2002-2011
Table 91: Type 2 Diabetes Therapeutics Market, Brazil, Sales Value ($m), 2011-2020
Table 92: Type 2 Diabetes Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2011-2020
Table 93: Type 2 Diabetes Therapeutics Market, Brazil, Patient Volume, (million) 2011-2020
Table 94: Type 2 Diabetes Therapeutics Market, Brazil, Treatment Usage Patterns (million), 2011-2020
Table 95: Type 2 Diabetes Therapeutics Market, India, Sales Value ($m), 2002-2011
Table 96: Type 2 Diabetes Therapeutics Market, India, Annual Cost of Therapy ($), 2002-2011
Table 97: Type 2 Diabetes Therapeutics Market, India, Patient Volume (million), 2002-2011
Table 98: Type 2 Diabetes Therapeutics Market, India, Treatment Usage Patterns (million), 2002-2011
Table 99: Type 2 Diabetes Therapeutics Market, India, Sales Value ($m), 2011-2020
Table 100: Type 2 Diabetes Therapeutics Market, India, Annual Cost of Therapy ($), 2011-2020
Table 101: Type 2 Diabetes Therapeutics Market, India, Patient Volume (million), 2011-2020
Table 102: Type 2 Diabetes Therapeutics Market, India, Treatment Usage Patterns (million), 2011-2020
Table 103: Type 2 Diabetes Therapeutics Market, China, Sales Value ($m), 2002-2011
Table 104: Type 2 Diabetes Therapeutics Market, China, Annual Cost of Therapy ($), 2002-2011
Table 105: Type 2 Diabetes Therapeutics Market, China, Patient Volume (million) 2002-2011
Table 106: Type 2 Diabetes Therapeutics Market, China, Treatment Usage Patterns (million), 2002-2011
Table 107: Type 2 Diabetes Therapeutics Market, China, Sales Value ($m), 2011-2020
Table 108: Type 2 Diabetes Therapeutics Market, China, Annual Cost of Therapy ($), 2011-2020
Table 109: Type 2 Diabetes Therapeutics Market, China, Patient Volume (million), 2011-2020
Table 110: Type 2 Diabetes Therapeutics Market, China, Treatment Usage Patterns (million), 2011-2020
Table 111: Type 2 Diabetes Therapeutics Market, Russia, Sales Value ($m), 2002-2011
Table 112: Type 2 Diabetes Therapeutics Market, Russia, Annual Cost of Therapy ($), 2002-2011
Table 113: Type 2 Diabetes Therapeutics Market, Russia, Patient Volume (million), 2002-2011
Table 114: Type 2 Diabetes Therapeutics Market, Russia, Treatment Usage Patterns (million), 2002-2011
Table 115: Type 2 Diabetes Therapeutics Market, Russia, Sales Value ($m), 2011-2020
Table 116: Type 2 Diabetes Therapeutics Market, Russia, Annual Cost of Therapy ($), 2011-2020
Table 117: Type 2 Diabetes Therapeutics Market, Russia, Patient Volume (million), 2011-2020
Table 118: Type 2 Diabetes Therapeutics Market, Russia, Treatment Usage Patterns (million), 2011-2020
Table 119: Type 2 Diabetes Therapeutics Market, Global, Characteristics of Ideal Drug that Would Satisfy the Unmet Needs, 2011
Table 120: Type 2 Diabetes Therapeutics Market, Global, Description of Ideal Drug that Would Satisfy the Unmet Needs, 2011
Table 121: Type 2 Diabetes Therapeutics Market, Global, Benchmarking Major Marketed Products, 2011
Table 122: Type 2 Diabetes, Global, Actos, Adverse Effects Incidence, 2011
Table 123: Type 2 Diabetes Therapeutics Market, Global, Avandia, Cardiovascular Adverse Effects Incidence, 2011
Table 124: Type 2 Diabetes Therapeutics Market, Global, Metformin, Adverse Effects Incidence, 2011
Table 125: Type 2 Diabetes Therapeutics Market, Global, Amaryl, Adverse Effects Incidence, 2011
Table 126: Type 2 Diabetes Therapeutics Market, Global, Amaryl, Regulatory Approval, 2011
Table 127: Type 2 Diabetes Therapeutics Market, Global, Glyburide, Clinical Study Details, 2011
Table 128: Type 2 Diabetes Therapeutics Market, Global, Glyburide, Clinical Study Details, 2011
Table 129: Type 2 Diabetes Therapeutics Market, Global, Glipizide, Clinical Study Details, 2011
Table 130: Type 2 Diabetes Therapeutics Market, Global, Precose, Clinical Study Details, 2011
Table 131: Type 2 Diabetes Therapeutics Market, Global, Glyset, Clinical Study Details, 2011
Table 132: Type 2 Diabetes Therapeutics Market, Global, Glyset, Regulatory Approval, 2011
Table 133: Type 2 Diabetes Therapeutics Market, Global, Basen, Regulatory Approval, 2011
Table 134: Type 2 Diabetes Therapeutics Market, Global, Januvia, Adverse Effects Incidence, 2011
Table 135: Type 2 Diabetes Therapeutics Market, Global, Januvia, Clinical Study Details as Monotherapy, 2011
Table 136: Type 2 Diabetes Therapeutics Market, Global, Januvia, Clinical Study Details as Add-on to Metformin and Rosiglitazone, 2011
Table 137: Type 2 Diabetes Therapeutics Market, Global, Januvia, Clinical Study Details as Add-on to Metformin, 2011
Table 138: Type 2 Diabetes Therapeutics Market, Global, Januvia, Clinical Study Details as Add-on to Pioglitaozone, 2011
Table 139: Type 2 Diabetes Therapeutics Market, Global, Januvia, Regulatory Approval, 2011
Table 140: Type 2 Diabetes Therapeutics Market, Global, Onglyza, Adverse Effects Incidence, 2011
Table 141: Type 2 Diabetes Therapeutics Market, Global, Galvus, Efficacy Monotherapy Trial, 2011
Table 142: Type 2 Diabetes Therapeutics Market, Global, Galvus, Efficacy Combination Trial, 2011
Table 143: Type 2 Diabetes Therapeutics Market, Global, Byetta, Efficacy, 2011
Table 144: Type 2 Diabetes Therapeutics Market, Global, Byetta, Adverse Effects Incidence, 2011
Table 145: Type 2 Diabetes Therapeutics Market, Global, Victoza, Adverse Effects Incidence, 2011
Table 146: Type 2 Diabetes Therapeutics Market, Global, Humalog, Clinical Study Details as a Monotherapy, 2011
Table 147: Type 2 Diabetes Therapeutics Market, Global, Humalog, Comparative Clinical Study Details in Combination with a Sulfonylurea, 2011
Table 148: Type 2 Diabetes Therapeutics Market, Global, Humulin, Regulatory Approval, 2011
Table 149: Type 2 Diabetes Therapeutics Market, Global, Novolog, Clinical Study Details, 2011
Table 150: Type 2 Diabetes Therapeutics Market, Global, Novolog, Clinical Study Details as a Pump Therapy, 2011
Table 151: Type 2 diabetes Therapeutics Market, Global, Novolog, Regulatory Approvals, 2011
Table 152: Type 2 Diabetes Therapeutics Market, Global, Apidra, Adverse Effects Incidence, 2011
Table 153: Type 2 Diabetes Therapeutics Market, Global, Apidra, Clinical Study Details, 2011
Table 154: Type 2 Diabetes Therapeutics Market, Global, Apidra, Regulatory Approvals, 2011
Table 155: Type 2 diabetes Therapeutics Market, Global, Welchol, Clinical Study Details, 2011
Table 156: Type 2 Diabetes Therapeutics Market, Global, Welchol, Regulatory Approvals, 2011
Table 157: Type 2 Diabetes Therapeutics Market, Global, Cycloset, Clinical Study Details, 2011
Table 158: Type 2 Diabetes Therapeutics Market, Global, Bydureon, (DURATION-2) Trial Efficacy, 2011
Table 159: Type 2 Diabetes Therapeutics Market, Global, Desirable Drug Delivery Methods for Diabetes are Currently Unavailable, 2011
Table 160: Type 2 Diabetes Therapeutics Market, Regulatory Filing, October 2011
Table 161: Type 2 Diabetes Therapeutics Market, Global, Phase III Pipeline, October 2011
Table 162: Type 2 Diabetes Therapeutics Market, Global, Phase II Pipeline, October 2011
Table 163: Type 2 Diabetes Therapeutics Market, Global, Phase I Pipeline, October 2011
Table 164: Type 2 Diabetes Therapeutics Market, Global, Preclinical and Discovery Pipeline, October, 2011
Table 165: Type 2 Diabetes Therapeutics Market, Global, Co-Development Agreements, 2010–2011
Table 166: Type 2 Diabetes Therapeutics Market, Global, Licensing Agreements, 2010–2011
Table 167: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials by Status, October 2011
Table 168: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials by Country, October 2011
Table 169: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials by Phase, October 2011
Table 170: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials by Sponsor Type, October 2011
Table 171: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials, Leading Sponsors, October 2011
Table 172: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials, Leading Company Sponsors, October 2011
Table 173: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials, Average Number of Patients Recruited, October 2011
Table 174: Type 2 Diabetes Therapeutics Market, Global, Merger and Acquisition Deals by Geography, 2008-2011
Table 175:Type 2 Diabetes Therapeutics Market, Global, Merger and Acquisition Deals by Geography, 2011
Table 176:Type 2 Diabetes Therapeutics Market, Global, Merger and Acquisition Deals by Deal Size, 2011
1.2 List of Figures
Figure 1: Type 2 Diabetes, Global, Treatment Guidelines, 2011
Figure 2: Type 2 Diabetes Therapeutics Market, Global, Sales Value ($bn), 2002-2011
Figure 3: Type 2 Diabetes Therapeutics Market, Global, Sales Value ($bn) by Country, 2002-2011
Figure 4: Type 2 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2011
Figure 5: Type 2 Diabetes Therapeutics Market, Global, Patient Volume (million), 2002-2011
Figure 6: Type 2 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2011
Figure 7: Type 2 Diabetes Therapeutics Market, Global, Market Drivers and Restraints, 2011
Figure 8: Type 2 Diabetes Therapeutics Market, Global, The Impact of Historical Events on the Market, 2011
Figure 9: Type 2 Diabetes Therapeutics Market, Global, Sales Value ($bn), 2011-2020
Figure 10: Type 2 Diabetes Therapeutics Market, Global, Sales Value ($bn) by Country, 2011-2020
Figure 11: Type 2 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2020
Figure 12: Type 2 Diabetes Therapeutics Market, Global, Patient Volume (million), 2011-2020
Figure 13: Type 2 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (million), 2011-2020
Figure 14: Type 2 Diabetes Therapeutics Market, Global, Future Market Drivers and Restraints, 2011-2020
Figure 15: Type 2 Diabetes Therapeutics Major Markets, Drug Sales ($bn), 2002-2020
Figure 16: Type 2 Diabetes Therapeutics Market, The US, Sales Value ($bn), 2002-2011
Figure 17: Type 2 Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2002-2011
Figure 18: Type 2 Diabetes Therapeutics Market, The US, Patient Volume (million), 2002-2011
Figure 19: Type 2 Diabetes Therapeutics Market, The US, Treatment Usage Patterns (million), 2002-2011
Figure 20: Type 2 Diabetes Therapeutics Market, The US, Market Drivers and Restraints, 2011
Figure 21: Type 2 Diabetes Therapeutics Market, The US, The Impact of Historical Events on the Market, 2011
Figure 22: Type 2 Diabetes Therapeutics Market, The US, Sales Value ($bn), 2011-2020
Figure 23: Type 2 Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2011-2020
Figure 24: Type 2 Diabetes Therapeutics Market, The US, Patient Volume (million), 2011-2020
Figure 25: Type 2 Diabetes Therapeutics Market, The US, Treatment Usage Patterns (million), 2011-2020
Figure 26: Type 2 Diabetes Therapeutics Market, The US, Future Market Drivers and Restraints, 2011-2020
Figure 27: Type 2 Diabetes Therapeutics Market, The US, Drug Sales ($bn), 2002-2020
Figure 28: Type 2 Diabetes Therapeutics Market, The UK, Sales Value ($m), 2002-2011
Figure 29: Type 2 Diabetes Therapeutics Market, The UK, Annual Cost of Therapy ($), 2002-2011
Figure 30: Type 2 Diabetes Therapeutics Market, The UK, Patient Volume (million), 2002-2011
Figure 31: Type 2 Diabetes Therapeutics Market, The UK, Treatment Usage Patterns (million), 2002-2011
Figure 32: Type 2 Diabetes Therapeutics Market, The UK, Market Drivers and Restraints, 2011
Figure 33: Type 2 Diabetes Therapeutics Market, The UK, The Impact of Historical Events on the Market, 2011
Figure 34: Type 2 Diabetes Therapeutics Market, The UK, Sales Value ($m), 2011-2020
Figure 35: Type 2 Diabetes Therapeutics Market, The UK, Annual Cost of Therapy ($), 2011-2020
Figure 36: Type 2 Diabetes Therapeutics Market, The UK, Patient Volume (million), 2011-2020
Figure 37: Type 2 Diabetes Therapeutics Market, The UK, Treatment Usage Patterns (million), 2011-2020
Figure 38: Type 2 Diabetes Therapeutics Market, The UK, Future Market Drivers and Restraints, 2011-2020
Figure 39: Type 2 Diabetes Therapeutics Market, The UK, Drug Sales ($m), 2002-2020
Figure 40: Type 2 Diabetes Therapeutics Market, Germany, Sales Value ($m), 2002-2011
Figure 41: Type 2 Diabetes Therapeutics Market, Germany, Annual Cost of Therapy ($), 2002-2011
Figure 42: Type 2 Diabetes Therapeutics Market, Germany, Patient Volume (million), 2002-2011
Figure 43: Type 2 Diabetes Therapeutics Market, Germany, Treatment Usage Patterns (million), 2002-2011
Figure 44: Type 2 Diabetes Therapeutics Market, Germany, Market Drivers and Restraints, 2011
Figure 45: Type 2 Diabetes Therapeutics Market, Germany, The Impact of Historical Events on the Market, 2011
Figure 46: Type 2 Diabetes Therapeutics Market, Germany, Sales Value ($m), 2011-2020
Figure 47: Type 2 Diabetes Therapeutics Market, Germany, Annual Cost of Therapy ($), 2011-2020
Figure 48: Type 2 Diabetes Therapeutics Market, Germany, Patient Volume (million), 2011-2020
Figure 49: Type 2 Diabetes Therapeutics Market, Germany, Treatment Usage Patterns (million), 2011-2020
Figure 50: Type 2 Diabetes Therapeutics Market, Germany, Future Market Drivers and Restraints, 2011-2020
Figure 51: Type 2 Diabetes Therapeutics Market, Germany, Drug Sales ($m), 2002-2020
Figure 52: Type 2 Diabetes Therapeutics Market, France, Sales Value ($m), 2002-2011
Figure 53: Type 2 Diabetes Therapeutics Market, France, Annual Cost of Therapy ($), 2002-2011
Figure 54: Type 2 Diabetes Therapeutics Market, France, Patient Volume (million), 2002-2011
Figure 55: Type 2 Diabetes Therapeutics Market, France, Treatment Usage Patterns (million), 2002-2011
Figure 56: Type 2 Diabetes Therapeutics Market, France, Market Drivers and Restraints, 2011
Figure 57: Type 2 Diabetes Therapeutics Market, France, The Impact of Historical Events on the Market, 2011
Figure 58: Type 2 Diabetes Therapeutics Market, France, Sales Value ($m), 2011-2020
Figure 59: Type 2 Diabetes Therapeutics Market, France, Annual Cost of Therapy ($), 2011-2020
Figure 60: Type 2 Diabetes Therapeutics Market, France, Patient Volume (million), 2011-2020
Figure 61: Type 2 Diabetes Therapeutics Market, France, Treatment Usage Patterns (million), 2011-2020
Figure 62: Type 2 Diabetes Therapeutics Market, France, Future Market Drivers and Restraints, 2011-2020
Figure 63: Type 2 Diabetes Therapeutics Market, France, Drug Sales ($m), 2002-2020
Figure 64: Type 2 Diabetes Therapeutics Market, Italy, Sales Value ($m), 2002-2011
Figure 65: Type 2 Diabetes Therapeutics Market, Italy, Annual Cost of Therapy ($), 2002-2011
Figure 66: Type 2 Diabetes Therapeutics Market, Italy, Patient Volume (million), 2002-2011
Figure 67: Type 2 Diabetes Therapeutics Market, Italy, Treatment Usage Patterns (million), 2002-2011
Figure 68: Type 2 Diabetes Therapeutics Market, Italy, Market Drivers and Restraints, 2011
Figure 69: Type 2 Diabetes Therapeutics Market, Italy, The Impact of Historical Events on the Market, 2011
Figure 70: Type 2 Diabetes Therapeutics Market, Italy, Sales Value ($m), 2011-2020
Figure 71: Type 2 Diabetes Therapeutics Market, Italy, Annual Cost of Therapy ($), 2011-2020
Figure 72: Type 2 Diabetes Therapeutics Market, Italy, Patient Volume (million), 2011-2020
Figure 73: Type 2 Diabetes Therapeutics Market, Italy, Treatment Usage Patterns (million), 2011-2020
Figure 74: Type 2 Diabetes Therapeutics Market, Italy, Future Market Drivers and Restraints, 2011-2020
Figure 75: Type 2 Diabetes Therapeutics Market, Italy, Drug Sales ($m), 2002-2020
Figure 76: Type 2 Diabetes Therapeutics Market, Spain, Sales Value ($m), 2002-2011
Figure 77: Type 2 Diabetes Therapeutics Market, Spain, Annual Cost of Therapy ($), 2002-2011
Figure 78: Type 2 Diabetes Therapeutics Market, Spain, Patient Volume (million), 2002-2011
Figure 79: Type 2 Diabetes Therapeutics Market, Spain, Treatment Usage Patterns (million), 2002-2011
Figure 80: Type 2 Diabetes Therapeutics Market, Spain, Market Drivers and Restraints, 2011
Figure 81: Type 2 Diabetes Therapeutics Market, Spain, The Impact of Historical Events on the Market, 2011
Figure 82: Type 2 Diabetes Therapeutics Market, Spain, Sales Value ($m), 2011-2020
Figure 83: Type 2 Diabetes Therapeutics Market, Spain, Annual Cost of Therapy ($), 2011-2020
Figure 84: Type 2 Diabetes Therapeutics Market, Spain, Patient Volume (million), 2011-2020
Figure 85: Type 2 Diabetes Therapeutics Market, Spain, Treatment Usage Patterns (million), 2011-2020
Figure 86: Type 2 Diabetes Therapeutics Market, Spain, Future Market Drivers and Restraints, 2011-2020
Figure 87: Type 2 Diabetes Therapeutics Market, Spain, Drug Sales ($m), 2002-2020
Figure 88: Type 2 Diabetes Therapeutics Market, Japan, Sales Value ($m), 2002-2011
Figure 89: Type 2 Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2011
Figure 90: Type 2 Diabetes Therapeutics Market, Japan, Patient Volume (million), 2002-2011
Figure 91: Type 2 Diabetes Therapeutics Market, Japan, Treatment Usage Patterns (million), 2002-2011
Figure 92: Type 2 Diabetes Therapeutics Market, Japan, Market Drivers and Restraints, 2011
Figure 93: Type 2 Diabetes Therapeutics Market, Japan, The Impact of Historical Events on the Market, 2011
Figure 94: Type 2 Diabetes Therapeutics Market, Japan, Sales Value ($m), 2011-2020
Figure 95: Type 2 Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011-2020
Figure 96: Type 2 Diabetes Therapeutics Market, Japan, Patient Volume (million), 2011-2020
Figure 97: Type 2 Diabetes Therapeutics Market, Japan, Treatment Usage Patterns (million), 2011-2020
Figure 98: Type 2 Diabetes Therapeutics Market, Japan, Future Market Drivers and Restraints, 2011-2020
Figure 99: Type 2 Diabetes Therapeutics Market, Japan, Drug Sales ($m), 2002-2020
Figure 100: Type 2 Diabetes Therapeutics Market, Brazil, Sales Value ($m), 2002-2011
Figure 101: Type 2 Diabetes Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2002-2011
Figure 102: Type 2 Diabetes Therapeutics Market, Brazil, Patient Volume (million), 2002-2011
Figure 103: Type 2 Diabetes Therapeutics Market, Brazil, Treatment Usage Patterns (million), 2002-2011
Figure 104: Type 2 Diabetes Therapeutics Market, Brazil, Market Drivers and Restraints, 2011
Figure 105: Type 2 Diabetes Therapeutics Market, Brazil, The Impact of Historical Events on the Market, 2011
Figure 106: Type 2 Diabetes Therapeutics Market, Brazil, Sales Value ($m), 2011-2020
Figure 107: Type 2 Diabetes Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2011-2020
Figure 108: Type 2 Diabetes Therapeutics Market, Brazil, Patient Volume (million), 2011-2020
Figure 109: Type 2 Diabetes Therapeutics Market, Brazil, Treatment Usage Patterns (million), 2011-2020
Figure 110: Type 2 Diabetes Therapeutics Market, Brazil, Future Market Drivers and Restraints, 2011-2020
Figure 111: Type 2 Diabetes Therapeutics Market, India, Sales Value ($m), 2002-2011
Figure 112: Type 2 Diabetes Therapeutics Market, India, Annual Cost of Therapy ($), 2002-2011
Figure 113: Type 2 Diabetes Therapeutics Market, India, Patient Volume (million), 2002-2011
Figure 114: Type 2 Diabetes Therapeutics Market, India, Treatment Usage Patterns (million), 2002-2011
Figure 115: Type 2 Diabetes Therapeutics Market, India, Market Drivers and Restraints, 2011
Figure 116: Type 2 Diabetes Therapeutics Market, India, The Impact of Historical Events on the Market, 2011
Figure 117: Type 2 Diabetes Therapeutics Market, India, Sales Value ($m), 2011-2020
Figure 118: Type 2 Diabetes Therapeutics Market, India, Annual Cost of Therapy ($), 2011-2020
Figure 119: Type 2 Diabetes Therapeutics Market, India, Patient Volume (million), 2011-2020
Figure 120: Type 2 Diabetes Therapeutics Market, India, Treatment Usage Patterns (million), 2011-2020
Figure 121: Type 2 Diabetes Therapeutics Market, India, Future Market Drivers and Restraints, 2011-2020
Figure 122: Type 2 Diabetes Therapeutics Market, China, Sales Value ($m), 2002-2011
Figure 123: Type 2 Diabetes Therapeutics Market, China, Annual Cost of Therapy ($), 2002-2011
Figure 124: Type 2 Diabetes Therapeutics Market, China, Patient Volume (million), 2002-2011
Figure 125: Type 2 Diabetes Therapeutics Market, China, Treatment Usage Patterns (million), 2002-2011
Figure 126: Type 2 Diabetes Therapeutics Market, China, Market Drivers and Restraints, 2011
Figure 127: Type 2 Diabetes Therapeutics Market, China, The Impact of Historical Events on the Market, 2011
Figure 128: Type 2 Diabetes Therapeutics Market, China, Sales Value ($m), 2011-2020
Figure 129: Type 2 Diabetes Therapeutics Market, China, Annual Cost of Therapy ($), 2011-2020
Figure 130: Type 2 Diabetes Therapeutics Market, China, Patient Volume (million), 2011-2020
Figure 131: Type 2 Diabetes Therapeutics Market, China, Treatment Usage Patterns (million), 2011-2020
Figure 132: Typ
GlobalData, the industry analysis specialist, has released its new report, “Type 2 Diabetes - Global Drug Forecasts and Treatment Analysis to 2020”. The report is an essential source of information and analysis on the global type 2 diabetes therapeutics market. The report provides comprehensive information on type 2 diabetes, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the global type 2 diabetes therapeutics market. It analyses the treatment usage patterns in the global type 2 diabetes therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global type 2 diabetes sector. It quantifies the unmet need in the global type 2 diabetes therapeutics market as well as in the individual markets such as the US and the top five countries in Europe, highlighting the opportunity for future players.
The Global Type 2 Diabetes Therapeutics Market was worth $23.7 Billion in 2011, Driven by the Growth in the Patient Volume and Annual Cost of Type 2 Diabetes Therapy
GlobalData analysis shows that the global type 2 diabetes therapeutics market was worth $23.7 billion in 2011. Between 2002 and 2011, the market grew at a rate of 11.8%. By 2020, the market is expected to be worth $45.1 billion, indicating a Compound Annual Growth Rate (CAGR) of 7.4% between 2011 and 2020.
The global type 2 diabetes therapeutics market is very attractive and has primarily been driven by the growth in patient volume and the annual cost of therapy. Patient volume has been driven by the increased incidence and prevalence of diabetes and the growth in treatment usage patterns, such as the diseased population, the treatment-seeking population, the diagnosed population and the prescription population. The annual cost of type 2 diabetes therapy was driven by the uptake of newly approved drugs, such as Actos and Avandia (until 2006), and the launch of new therapies, such as Levemir, Byetta, Januvia, and Victoza. The annual cost of therapy was also driven by the increased use of multiple drugs per patient and the adoption of combination therapies, such as Actoplusmet (pioglitazone and metformin), Avandamet (rosiglitazone and metformin), Janumet (sitagliptin and metformin) and Duetact (pioglitazone and glimepiride) in the first-line and second-line treatment of type 2 diabetes patients.
Metformin, alone or in combination with other oral agents, has become the standard of care for the first-line treatment of type 2 diabetes patients. Similarly, metformin in combination with DPP4 inhibitors or GLP-1 analogs has become one of the most commonly prescribed treatment options for type 2 diabetes.
In 2011, within the countries analyzed in this report (the US, EU5, Japan and BRIC countries), the US was the leading market with an estimated market share of 52.7%. Japan was the second leading market with an approximate market share of 12.8%, closely followed by Germany with an approximate market share of 7.5%.
In 2011, Lantus was the leading drug, with approximate sales worth $3.6 billion and a market share of 18%. Januvia/Janumet, the DPP4 inhibitor was the second leading drug, with approximate sales of $3.4 billion and a market share of 17.1%. Actos was the third leading drug, with an approximate sales value of $1.9 billion and a market share of 9.6%.
Novo Nordisk
Amylin Pharmaceuticals
Takeda Pharmaceuticals
Boehringer Ingelheim
Eli Lilly and Company
GlaxoSmithKline
Novartis
Sanofi
F. Hoffmann La Roche
Bristol-Myers Squibb
Johnson & Johnson (J&J)
Astellas Pharma Inc.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
